J&J Wins FDA Approval for Diabetes Combo Drug

Aug 12, 2014

Market Watch

J&J’s Janssen Pharmaceuticals unit was granted FDA approval for Invokamet, a fixed-dose therapy combining canagliflozin and metformin hydrochloride in a single tablet, for the treatment of adults with type 2 diabetes.

According to J&J, Invokamet combines the SGLT2 blocker canagliflozin (approved in March 2013) with the commonly prescribed treatment metformin, creating a single tablet that lowered blood sugar, lowered blood pressure and reduced body weight in Phase III trials.

Invokamet is the first fixed-dose combination of an SGLT2 inhibitor with metformin approved in the United States.

Read the press release

Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.


No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments